Similarly, patients with isolated GHD demonstrated equivalent levels of deficit in QoL-AGHDAutility at baseline and comparable gain during GH treatment in comparison with patients with multiple pituitary hormone deficiency. This evidence concerns the gene GH1 and hypopituitarism.